Spero Therapeutics, Inc.
SPRONASDAQHealthcare● Active
$2.74
$-0.08(-2.84%)
Market Cap$158650091
P/E Ratio—
52W High$3.22
52W Low$1.8
Spero Therapeutics, Inc. (SPRO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SPRO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $59.62M | $47.98M | $103.78M | $48.58M | $3.07M |
| Cost of Revenue | $0.00M | $96.76M | $51.44M | $0.00M | $0.00M |
| Gross Profit | $59.62M | ($48.78M) | $52.34M | $48.58M | $3.07M |
| Gross Margin %(computed) | 100.00% | -101.67% | 50.43% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $38.47M | $96.76M | $51.44M | $47.59M | $64.53M |
| G&A Expenses | $21.18M | $22.91M | $24.99M | $36.48M | $41.70M |
| Total Operating Expenses | $59.64M | $24.58M | $30.86M | $90.78M | $91.04M |
| Operating Income | ($0.02M) | ($73.36M) | $21.48M | ($42.20M) | ($87.97M) |
| Operating Margin %(computed) | -0.04% | -152.91% | 20.70% | -86.86% | — |
| Interest Income | $2.51M | $4.74M | $3.94M | $1.11M | $0.35M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $2.60M | $1.94M |
| Income Before Tax | $8.83M | ($68.57M) | $25.40M | ($46.41M) | ($89.76M) |
| Income Tax Expense | $0.26M | $0.00M | $2.60M | $0.00M | $0.00M |
| Net Income | $8.57M | ($68.57M) | $22.81M | ($46.41M) | ($89.76M) |
| Net Margin %(computed) | 14.38% | -142.91% | 21.98% | -95.55% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 |
| Wtd Avg Shares | 56.02M | 54.04M | 52.70M | 37.59M | 30.90M |
| EBITDA | ($0.02M) | ($72.48M) | $27.15M | ($42.94M) | ($87.17M) |
| EBITDA Margin %(computed) | -0.04% | -151.08% | 26.16% | -88.39% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Spero Therapeutics, Inc. data
About Spero Therapeutics, Inc. (SPRO) Income Statement
Spero Therapeutics, Inc. (SPRO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SPRO reported revenue of $0.06B, gross profit of $0.06B (gross margin 100.00%), and net income of $0.01B — a net profit margin of 14.38%.
Frequently asked questions
SPRO · 4 questionsSpero Therapeutics, Inc. (SPRO) reported revenue of $0.06B for 2025, up 24.3% year-over-year.
SPRO revenueSPRO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09